Literature DB >> 20502381

Expression of keratinocyte growth factor and its receptor in noncholesteatomatous and cholesteatomatous chronic otitis media.

Tomomi Yamamoto-Fukuda1, Haruo Takahashi, Mariko Terakado, Yoshitaka Hishikawa, Takehiko Koji.   

Abstract

INTRODUCTION: The purpose of the study was to test a hypothesis that the keratinocyte growth factor (KGF) is a key factor in the pathologic difference between cholesteatomatous (C-COM) and noncholesteatomatous chronic otitis media (NC-COM). We compared the expression levels of KGF and its receptor (KGFR) and the proliferation activity of epithelial cells between NC-COM and C-COM.
METHODS: The epithelial lesion was surgically excised with subepithelial tissue from 18 patients with NC-COM and 70 patients with C-COM, and was processed for immunohistochemistry for KGF and KGFR. We also examined the proportion of proliferating epithelial cells using Ki-67 and the extent of infiltrating B and T cells.
RESULTS: Keratinocyte growth factor was positive in 5 of 18 (28%) NC-COM specimens and in 61 of 69 (88%) C-COM specimens (p < 0.0001). Furthermore, 37 (60%) C-COM specimens were positive for KGFR, but none of NC-COM were positive (0%; p < 0.01). The Ki-67 labeling index (LI) was significantly smaller in NC-COM than in C-COM (p < 0.001). B-Cell LI was almost similar in the 2 groups. T-Cell LI was significantly higher in C-COM than in NC-COM (p < 0.0001). Interestingly, T-cell LI in NC-COM was higher in KGF-positive tissues than in KGF-negative tissues (p < 0.05).
CONCLUSION: The results indicated that coexpression of KGF and KGFR seems to explain the pathologic difference between C-COM and NC-COM, and that KGF may play an important role in the development of cholesteatoma.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20502381     DOI: 10.1097/MAO.0b013e3181dd15ef

Source DB:  PubMed          Journal:  Otol Neurotol        ISSN: 1531-7129            Impact factor:   2.311


  5 in total

1.  Keratinocyte Growth Factor (KGF) Modulates Epidermal Progenitor Cell Kinetics through Activation of p63 in Middle Ear Cholesteatoma.

Authors:  Tomomi Yamamoto-Fukuda; Naotaro Akiyama; Masahiro Takahashi; Hiromi Kojima
Journal:  J Assoc Res Otolaryngol       Date:  2018-03-16

2.  Cholesteatoma-associated fibroblasts modulate epithelial growth and differentiation through KGF/FGF7 secretion.

Authors:  Salvatore Raffa; Laura Leone; Cristina Scrofani; Simonetta Monini; Maria Rosaria Torrisi; Maurizio Barbara
Journal:  Histochem Cell Biol       Date:  2012-04-06       Impact factor: 4.304

3.  Cytokeratin 13, Cytokeratin 17, and Ki-67 Expression in Human Acquired Cholesteatoma and Their Correlation With Its Destructive Capacity.

Authors:  Mahmood A Hamed; Seiichi Nakata; Kazuya Shiogama; Kenji Suzuki; Ramadan H Sayed; Yoichi Nishimura; Noboru Iwata; Kouhei Sakurai; Badawy S Badawy; Ken-Ichi Inada; Hayato Tsuge; Yutaka Tsutsumi
Journal:  Clin Exp Otorhinolaryngol       Date:  2017-01-12       Impact factor: 3.372

Review 4.  Review of potential medical treatments for middle ear cholesteatoma.

Authors:  Matthias Schürmann; Peter Goon; Holger Sudhoff
Journal:  Cell Commun Signal       Date:  2022-09-19       Impact factor: 7.525

Review 5.  Pathogenesis and Bone Resorption in Acquired Cholesteatoma: Current Knowledge and Future Prospectives.

Authors:  Mahmood A Hamed; Seiichi Nakata; Ramadan H Sayed; Hiromi Ueda; Badawy S Badawy; Yoichi Nishimura; Takuro Kojima; Noboru Iwata; Ahmed R Ahmed; Khalid Dahy; Naoki Kondo; Kenji Suzuki
Journal:  Clin Exp Otorhinolaryngol       Date:  2016-07-21       Impact factor: 3.372

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.